AbbVie/ABBV

$153.81

-0.98%
-
1D1W1MYTD1YMAX

About AbbVie

AbbVie Inc. is a diversified research-based biopharmaceutical company. The Company is engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. It offers products in therapeutic categories, including immunology, which include Humira, Skyrizi and Rinvoq; oncology, which include Imbruvica, Venclexta/Venclyxto, Epkinly and Elahere; aesthetics products, which include Botox Cosmetic, The Juvederm Collection of Fillers and others; neuroscience, which include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy and Qulipta; eye care, which consists of Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis and Other eye care, and other key products, which include Mavyret/Maviret, Creon, Lupron, Linzess/Constella and Synthroid. It also offers investigational asset named NX-13, oral NLRX1 agonist (a member of the NOD-like receptor family), which is in Phase II for the treatment of ulcerative colitis (UC) and Crohn's disease (CD).

Ticker

ABBV

Sector

Healthcare

Trading on

NYSE

Industry

Biotechnology & Drugs

CEO

Richard Gonzalez

Employees

50,000

Headquarters

North chicago, United States

AbbVie Metrics

BasicAdvanced
$277B
Market cap
46.78
P/E ratio
$3.36
EPS
0.57
Beta
$5.99
Dividend rate
3.95%
Dividend yield
$277B
0.57284
$182.89
$130.96
5.7M
$5.99
0.936
0.834
796.865
924.204
181.01%
102.781
8.95%
4.24%
55.92%
5.61%
46.778
5.098
34.635
24.673
3.98%
3.81%
3.95%
-4.12%
-20.78%
5.85%
-0.06%
7.84%

What the Analysts think about AbbVie

Analyst Ratings

Majority rating from 30 analysts.
Buy

Price Targets

Average projection from 25 analysts.
18.93% upside
High $207.00
Low $161.00
$153.81
Current price
$182.92
Average price target

AbbVie Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
11.12% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$12B
-13.92%
Net income
$1.4B
66.55%
Profit margin
11.12%
93.73%

AbbVie Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 3.76%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$2.91
$2.95
$2.79
$2.31
-
Expected
$2.81
$2.86
$2.77
$2.23
$3.05
Surprise
3.69%
3.25%
0.84%
3.76%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for AbbVie stock?

AbbVie (ABBV) has a market cap of $277B as of May 29, 2024.

What is the P/E ratio for AbbVie stock?

The price to earnings (P/E) ratio for AbbVie (ABBV) stock is 46.78 as of May 29, 2024.

Does AbbVie stock pay dividends?

Yes, the AbbVie (ABBV) stock pays dividends to shareholders. As of May 29, 2024, the dividend rate is $5.99 and the yield is 3.95%. AbbVie has a payout ratio of 181.01% on a trailing twelve-month basis.

When is the next AbbVie dividend payment date?

The next AbbVie (ABBV) dividend payment date is unconfirmed.

What is the beta indicator for AbbVie?

AbbVie (ABBV) has a beta rating of 0.57. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the AbbVie stock price target?

The target price for AbbVie (ABBV) stock is $182.92, which is 18.19% above the current price of $154.77. This is an average based on projections from 25 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell AbbVie stock

Buy or sell AbbVie stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing